Download Chapter-3-Pharmacodynamics.docx
of 8
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Similar Documents
  CHAPTER 3  –  PHARMACODYNAMICS 1 ©RAT PHARMACODYNAMIC CONCEPTS Pharmacodynamics  –  study of biochemical, cellular, and physiological effect of drugs and mechanisms of action Drug receptor or drug target  –  complex with which the drug interacts -   Often on the surface of the cell Acceptors  –  do not cause any change in response but alter pharmacokinetics of a drug’s actions (e.g. albumin)  Therapeutic biologics  –  genetically engineered enzymes and monoclonal antibodies Gene therapy products  –  uses viruses as vectors to replace genetic mutations PHYSIOLOGIC RECEPTORS Physiological receptors  –  drug receptors that serve as receptors for endogenous regulatory ligands Agonists  –  Drugs that bind physiologic receptors and mimic regulatory effects -   Primary agonist  –  binds to the same recognition site as endogenous agonist -   Allosteric (allotopic) agonist  –  bind to a different region on a receptor Antagonists  –  drugs that block or reduce action of agonist -   Syntopic interaction  –  from competition for same overlapping site -   Allosteric antagonism  –  occur by interacting with other sites -   Functional antagonism  –  inhibiting effect of agonist Partial agonist  –  only partially effective as agonist Inverse agonist  –  stabilize receptors with constitutive activity into inactive conformation Partial agonist + Inverse agonist  –  behave as antagonist in the presence of full agonist SPECIFICITY OF DRUG RESPONSES Dissociation constant  –  affinity of drug to its receptor; measurement of strength of reversible interaction Chemical structure  –  determines affinity of drug for its receptor and its intrinsic activity -   Also contributes to drug specificity Drugs w broad specificity -   Enhances clinical utility -   Contribute to adverse side effects Amiodarone  –  one drug that interacts w/ multiple receptors -   For cardiac arrythmias -   Similar structure to thyroid hormone Sotalol  –  prescribes as racemic mixture -   D- and L- enantiomers are equipotent as K channel blockers -   L-enantiomer  –  more powerful potent B-adrenergic antagonist Multiple mechanisms of action depend on: -   Receptor specificity -   Tissue-specific expression of receptors -   Drug access -   Drug concentrations in different tissues -   Pharmacogenetics -   Interactions w/ other drugs Downregulation or desensitization  –  caused by chronic administration of drug -   Chronic use of nitrovasodilators for angina results in complete tolerance, a process nown as tachyphylaxis Drug resistance may also develop because of: -   Pharmacokinetic mechanisms (metabolized rapidly) -   Mechanisms that prevent drug from reaching receptor -   Cancer cells w/ drug-resistant mutations Some effects do not occur by receptor: -   Aluminum and magnesium hydroxide  –  reduce gastric acid chemically -   Mannitol  –  acts osmotically -   Antibiotics, antivirals, antiparasitics  –  targets receptors or cell processes critical for infective agent only Resistance to antibiotics/antivirals can occur by: -   Mutation of target receptor -   ↑  expression of enzymes that degrade or ↑ efflux of drug  -   Development of alternative biochemical pathways STRUCTURE-ACTIVITY RELATIONSHIPS AND DRUG DESIGN Orphan receptor  –  ligands are unknown Chemical structure  –  determines affinity and intrinsic activity of a drug -   Minor modification to molecule may result to major changes -   Therapeutically useful antagonists  –  developed by chemical modification of physiological agonist Pharmacophore  –  use computer analysis to identify chemical properties for optimal action at the receptor QUANTITATIVE ASPECTS OF DRUG INTERACTIONS WITH RECEPTORS Receptor occupancy theory  –   drug’s response emanat es from receptor occupied by the drug -   Basis is the law of mass action Dose-response curve  –  observed effect of a drug as a function of its concentration in the receptor compartment Hormesis  –  drugs that cause low-dose stimulation and high-dose inhibition -   U-shaped relationships (the figure on the left; A)  Affinity, Efficacy, and Potency Drug-receptor reaction is characterized by: 1.   Binding of drug to receptor 2.   Generation of a response L  –  ligand R  –  receptor LR reaction  –  governed by chemical property of affinity LR* - produced in proportion of LR and leads to a response  CHAPTER 3  –  PHARMACODYNAMICS 2 ©RAT -   Illustrates reliance of affinity of L with R on forward association rate and reverse/dissociation rate Potency  –  when two drugs produce equivalent responses, the drug whose dose-response curve lies to the left is more potent Efficacy  –  capacity of drug to activate receptor and generate response -   Full agonist  –  high efficacy -   Partial agonist  –  low intrinsic efficacy -   Antagonist  –  exhibits zero efficacy -   Drug X is more efficacious than drug Y Quantifying Agonism Describe agonist response by determining half-maximally effective concentration (EC50) Can also compare maximal asymptotes in a system -   Advantage: property depends solely on efficacy Drug potency  –  mixed function of affinity and efficacy Quantifying Antagonism  Competitive antagonism  –  drug with affinity for a receptor but lacking intrinsic efficacy competes for agonist for primary binding site -   Characteristic pattern  –  concentration-dependent production of a parallel shift to the right of agonist dose-response curve with no change in maximal response o   Magnitude of rightward shift depends on concentration of antagonist and its affinity -   Will reduce response to zero Partial agonist  –  can compete with full agonist -   Increasing concentrations of partial agonist will inhibit response to a finite level -   Used therapeutically to buffer response -   Vareniciline  –  partial agonist used in smoking cessation therapy o   Blocks effect of high dose nicotine Noncompetitive antagonism  –  an antagonist that dissociates very slowly so that action is prolonged -   Maximal response of agonist will be depressed at some antagonist concentration -   Irreversible antagonist  –  competes for the same binding site o   Same pattern as noncompetitive antagonism Allosteric or allotopic antagonist  –  also produces noncompetitive antagonism -   Binds to a site distinct from primary agonist, changing the affinity of the receptor for agonist Allosteric agonist or coagonist  –  drug binding at allosteric site that potentiates effect of primary agonist Affinity of competitive antagonist (K1)  –  determined in radioligand binding assay or by measuring functional response of a system to a drug -   As more antagonist is added, higher concentration of agonist is needed to produce equivalent response -   Extent of rightward shift  –  measure of affinity of inhibitor  Additivity and Synergism: Isobolograms  Drugs with different mechanisms of actions used in combination may be used to achieve additive and possitve synergistic effects -   Permits use of reduced concentrations Positive synergism  –  superadditive effects of drugs used in combination Negative synergism or subadditive effects  –  efficacy is less Isobologram  –  line connection EC50 of 2 drugs (Figure in the next page) -   Describes concentrations that will achieve half-maximal response when A and B are used in combination  CHAPTER 3  –  PHARMACODYNAMICS 3 ©RAT If A and B are superadditive: -   concentrations of A and B needed needed to achieve response will fall below additive response line If A and B are subadditive: -   concentrations will lie above additive response line PHARMACODYNAMIC VARIABILITY: INDIVIDUAL AND POPULATION PHARMACODYNAMICS Drug responsiveness may change because of: -   disease -   age -   previous drug administration Correlation of drug levels with efficacy and toxicity must be interpreted in the context of pharmacodynamic variability in population -   analyzed by quantal concentration-effect curve Median effective dose (ED50)  –  dose of a drug required to produce a specified effect in 50% of population Median lethal does (LD50)  –  determined in experimental animals LD50/ED50 ratio  –  indication of therapeutic index -   reflects how selective drug is producing its desired effects Therapeutic window  –  range of steady-state concentrations of drug that provides therapeutic efficacy with minimal toxicity Clinical therapeutic index - concentration of drug required to produce toxic effects compared with concentration required for therapeutic effects Population therapeutic window  –  concentrations at which the likelihood of efficacy is high and probability of adverse effects is low -   complemented by monitoring appropriate clinical and surrogate markers for drug effect(s) Drug Interactions and Combination Therapy   Drug interactions may be: -   pharmacokinetic  –  delivery of drug to site of action is altered -   Pharmacodynamic  –  response of the drug target is modified by second drug Combination therapy  –  optimal treatment of many conditions -   Some combinations cause adverse effects: o   Nitrovasodilators  –  vasodilation via NO-dependent elevation of cGMP o   Sildenafil, tadalfil, vardenafil  –  result from inhibition of PDE5 that hydrolyzes CGMP to 5GMP o   Coadministration  –  severe hypotension Warfarin  –  narrow margin between inhibition of clot formation and bleeding complication -   Alterations in dietary vitamin K may affect pharmacodynamics o   Antibiotics that alter intestinal flora    ↓  Vit K   increased effect of warfarin -   NSAIDS - ↑  risk of GI bleeding -   Aspirin  –  increases incidence of bleeding MECHANISM OF DRUG ACTION RECEPTORS THAT AFFECT CONCENTRATIONS OF ENDOGENOUS LIGANDS a-methyltyrosine, cocaine, emphetamine, selegiline  –  acts on adrenergic neurotransmission Vasoactive peptides, lipid-derived autocoids  –  affects synthesis and degradation of circulating mediators DRUG RECEPTORS ASSOCIATED WITH EXTRACELLULAR PROCESSES Many widely used drugs target enzymes and molecules that control extracellular processes: -   Thrombosis, inflammation, immune response -   Coagulation system RECEPTORS UTILIZED BY ANTI-INFECTIVE AGENTS Anti-infective agents target receptors that are microbial proteins -   Key enzymes required by infectious agent but not critical for the host Novel approach  –  genetically engineer vector organism to be resistant to infection (such as CRISPR-Cas9 System) RECEPTORS THAT REGULATE IONIC MILLIEU Receptors are ion pumps expressed only in specialized cells Most diuretics  –  directly affects ion pumps and transporters Esomeprazole  –  H-K ATPAse pump inhibitor in gastric parietal cell -   Reduces gastric secretion by 80-95% INTRACELLULAR PATHWAYS ACTIVATED BY PHYSIOLOGICAL RECEPTORS Signal Transduction Pathways  Largest number of drug receptors are physiological receptors that transduce signals; two major functions: -   Ligand binding -   Message propagation Two functional domains within receptor: -   Ligand binding domain (LBD) -   Effector domain Regulatory actions of receptors may be exerted on: -   Cell target -   Effector protein -   Transducers  –  intermediary cell signaling molecules Second messenger  –  cellular effector protein that is not the ultimate physiologic target -   Convey information and integrate multiple signals Compartmentation  –  constrained diffusion and intracellular actions -   Selective localization of complexes Scaffolds or anchoring proteins  –  proteins designed to localize signaling pathways  CHAPTER 3  –  PHARMACODYNAMICS 4 ©RAT STRUCTURAL AND FUNCTIONAL FAMILIES OF PHYSIOLOGICAL RECEPTORS Receptors for physiological regulatory molecules  –  assigned to functional families that share common mechanisms G Protein-Coupled Receptors  GPCR  –  seven a-helices -   Important regulators of nerve activity in CNS -   Receptors for NTs in the peripheral autonomic NS GPCR subtypes A1, a2, B adrenergic receptors differ in: -   Ligand selectivity -   Coupling to G proteins Terbutaline  –  B2 adrenergic receptor agonist -   Bronchodilator in the treatment of asthma Use of B1-selective antagonist  –  minimizes bronchoconstriction in patients treated for hypertension or angina Receptor dimerization  GPCRS undergo both homo and heterodimerization -   Dimerization  –  regulatesL o   affinity and specificity of G proteins o   sensitivity of receptors to phosphorylation o   binding of arrestin G Proteins  G proteins  –  signal transducers; heterotrimer consisting of: -   a subunit  –  confers specific recognition -   B and Y subunit  –  confer membrane localization by prenylation of Y subunit In the basal state  –   α  subunit is bound to GDP a subunit has 4 families -   Gas  –  activates AC -   Gai  –  inhibits AC -   Gaq  –  activates all forms of PLC β  -   G12/13  –  couple to GEFS (p115RhoGEF for small GTP-binding proteins Rho and Rac) K and Ca channels, P13K  –  some of the effectors of free By dimer Endocytosis of GPCRS in cAMP signaling   prolong signaling and lend “spatial coding” to distal signaling   Second-Messenger Systems Cyclic amp  –  synthesized by AC; mediated by Gas and inhibited by Gia AC has three major targets in most cells: PKA, GEFS termed EPACS, and CREB -   CNG, HCN, cyclic nucleotide regulated PDEs  –  targets in cells w/ specialized function PKA  –  two catalytic (C) subunits reversibly bound to regulatory (R) to form R2C2 -   4 cAMP bind to R2C2   2 per R subunit   R has lower affinity for C   Active C subunits  –  phosphorylate serine and threonine residues -   Isoforms o   a and B isoforms of regulatory subunit o   3 C subunit isoforms  –  Ca, CB, and CY -   Modulated by localization mediated by AKAPs
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!